PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Jing Christine Ye,
Noa Biran,
Sandhya Nair,
Xiwu Lin,
Keqin Qi,
Anil Londhe,
Eric Ammann,
Thomas Renaud,
Colleen Kane,
Trilok Parekh,
Kathleen Gray,
Steve Peterson,
Luciano Costa
Affiliations
Jing Christine Ye
1 University of Michigan, Rogel Cancer Center at the time that the work was performed, Ann Arbor, United States
Noa Biran
2 Hackensack University Medical Center, Hackensack, United States
Sandhya Nair
3 Janssen Pharmaceutica NV, Beerse, Belgium
Xiwu Lin
4 Janssen Global Services, Horsham, United States
Keqin Qi
5 Janssen Research & Development, Titusville, United States
Anil Londhe
5 Janssen Research & Development, Titusville, United States
Eric Ammann
6 Janssen Global Services, Raritan, United States
Thomas Renaud
7 Janssen Research & Development, Raritan, United States
Colleen Kane
8 Janssen Research & Development, Spring House, United States
Trilok Parekh
9 Janssen Research & Development, Bridgewater, United States
Kathleen Gray
8 Janssen Research & Development, Spring House, United States
Steve Peterson
10 Janssen Research & Development, Horsham
Luciano Costa
11 University of Alabama at Birmingham, Birmingham, United States
